Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dominique Hodeige"'
Publikováno v:
European Journal of Clinical Investigation. 28:798-806
BACKGROUND: As endothelin-1 exerts positive inotropic effects, the present study evaluated whether the hypotensive effects of the endothelin-1 receptor antagonist bosentan were partially related to a decrease in myocardial performance. METHODS: In gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ff8c00b1a0404b8a8360fbc8233994e
https://doi.org/10.1046/j.1365-2362.1998.00374.x
https://doi.org/10.1046/j.1365-2362.1998.00374.x
Autor:
Julian Donckier, PE Massart, Henri Van Mechelen, Guy R. Heyndrickx, André A. Charlier, Jean-Marie Ketelslegers, Dominique Hodeige
Publikováno v:
Journal of Hypertension. 16:835-841
OBJECTIVE: To evaluate whether the cumulative hypotensive effect of the endothelin-1 receptor antagonist bosentan, previously demonstrated in the presence of an angiotensin converting enzyme inhibitor, persists under angiotensin II receptor blockade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679c0be64e2ad4f505cb84c52a1eff3a
https://doi.org/10.1097/00004872-199816060-00015
https://doi.org/10.1097/00004872-199816060-00015
Autor:
Jean-Marie Ketelslegers, André A. Charlier, PE Massart, Henri Van Mechelen, Olivier Laloux, Jean-Paul Clozel, Julian Donckier, Dominique Hodeige, Guy R. Heyndrickx
Publikováno v:
Circulation. 96:1250-1256
Background Endothelin-1 (ET-1) may play a role in hypertension. ET-1 receptor antagonism by bosentan lowers blood pressure in hypertension. We evaluated whether the effect of bosentan is still observed under ACE inhibitors (ACEI). Methods and Results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4577f29b144e94263fb457cbe6b8e0
https://doi.org/10.1161/01.cir.96.4.1250
https://doi.org/10.1161/01.cir.96.4.1250
Autor:
Guy R. Heyndrickx, Dominique Hodeige
Publikováno v:
Journal of Thrombosis and Thrombolysis. 4:123-125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f369adb623631c498596009a5f817ecf
https://doi.org/10.1023/a:1017599812408
https://doi.org/10.1023/a:1017599812408
Publikováno v:
European journal of pharmacology. 279(1)
We have assessed the ability of amiodarone and the new amiodarone-like antiarrhythmic agent, SR 33589 (N,N-dibutyl-3-[4-((2-butyl-5-methylsulphonamido)benzofuran-3-yl-c arbonyl) phenoxy]propylamine), to inhibit the effects of adrenoceptor stimulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56a0a5463c3f5241b4968528cabec4a7
https://pubmed.ncbi.nlm.nih.gov/7556379
https://pubmed.ncbi.nlm.nih.gov/7556379
Autor:
Jean Richard, Allan S. Manning, Pierre Chatelain, Jean Pierre Heyndrickx, Dominique Hodeige, Vincent Thisse
Publikováno v:
Journal of cardiovascular pharmacology. 25(2)
We compared the electrophysiological effects of a new amiodarone-like agent, SR 33589, with those of amiodarone. Mongrel dogs were anesthetized with chloralose, and electrodes were implanted in right atrium and ventricle for electrical stimulation an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38b5a2d0fe737620433287f6c688052
https://pubmed.ncbi.nlm.nih.gov/7752650
https://pubmed.ncbi.nlm.nih.gov/7752650
Publikováno v:
Pharmacology. 48(1)
We have investigated the effects of a novel calcium antagonist, fantofarone (SR 33557) on myocardial oxygen consumption (MO2C) and coronary blood flow in anaesthetized dogs during periods of normal and elevated heart rate. 25 micrograms/kg i.v. fanto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d163979257f36e7dfc2a94855ad39bd8
https://pubmed.ncbi.nlm.nih.gov/8309987
https://pubmed.ncbi.nlm.nih.gov/8309987